MD Anderson Cancer Center
Combination stifles CLL
The targeted therapy ibrutinib and the antibody rituximab knock down chronic lymphocytic leukemia in 90% of patients in a clinical trial. Jan Burger, M.D., Ph.D., explains.
Video is loading...
Title: Combination stifles CLL
Summary: The targeted therapy ibrutinib and the antibody rituximab knock down chronic lymphocytic leukemia in 90% of patients in a clinical trial. Jan Burger, M.D., Ph.D., explains.
Keywords: MD Anderson,cancer center,cancer,cancer treatment,chronic lymphocytic leukemia,ibrutinib,cll,ash, extComm, Communications - External
Transcript: